Brief: AB Science Says Masitinib Extended Survival In Als By 25 Months Relative To Placebo
19/07/2021 17:22
July 19 (Reuters) - AB Science SA ABS.PA :
* REG-AB SCIENCE ANNOUNCES THE PUBLICATION OF NEW SURVIVAL DATA SHOWING THAT
MASITINIB EXTENDED SURVIVAL IN AMYOTROPHIC LATERAL SCLEROSIS (ALS) BY 25 MONTHS
RELATIVE TO PLACEBO
* LONG-TERM FOLLOW-UP OF 75 MONTHS SHOWED THAT MASITINIB EXTENDED SURVIVAL
IN
AMYOTROPHIC LATERAL SCLEROSIS BY 25 MONTHS RELATIVE TO PLACEBO, PROVIDED THAT
TREATMENT STARTS EARLY IN DISEASE COURSE
* PUBLICATION OF LONG-TERM FOLLOW-UP SURVIVAL DATA IN PEER-REVIEWED JOURNAL
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS
Source text for Eikon: ID:nGNE5F7816
Further company coverage: ABS.PA
(Gdansk Newsroom)
((Gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
Recent news on AB Science SA
See all newsBrief: AB Science Temporarily Halts Europe Clinical Trials Ahead Of Strategic Reorganization
Brief: AB Science Says FDA Granted Status Of Minor Use In Major Species For Masivet
Brief: AB Science Says Co Received Japanese Patent Protection To Use Masitinib In Progressive MS Until 2041
Brief: AB Science Phase 1 AML Study Of AB8939 Shows 100% Partial Response Rate
Brief: AB Science Receives Notice Of Allowance For European Patent Covering Masitinib Until 2040 In Treatment Of Sickle Cell Disease